Peer-reviewedCC BY-NC-NDInternal Medicine
Successful Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer in a Patient with Combined Pulmonary Fibrosis and Emphysema: A Case Report
Abstract
Interstitial lung disease (ILD) is a major risk factor for severe radiation pneumonitis (RP) during thoracic radiotherapy. We herein report a case of limited-stage small cell lung cancer with coexisting pulmonary fibrosis and emphysema treated with concurrent chemoradiotherapy. The patient exhibited fibrotic lesions consistent with a usual interstitial pneumonia pattern and a mild 18F-fluorodeoxyglucose uptake, indicating an elevated risk of RP. However, high-grade RP did not develop, likely because radiation exposure to nontarget lungs was limited. The irradiation field was spatially separated from the fibrotic regions. This case suggests that carefully selected patients with ILD may tolerate concurrent chemoradiotherapy.
Related
- Successful conservative management of hepatic portal venous gas complicating severe immune-related gastrointestinal injury during pembrolizumab-based concurrent chemoradiotherapy for cervical cancer: a mechanistic case report
- Prediction Model for Detecting Active Pulmonary Tuberculosis in Patients With Head and Neck Cancer Prior to Concurrent Chemoradiotherapy
- Combined Active Bone Marrow‐Sparing Radiotherapy and Prophylactic PEG‐rhG‐CSF to Reduce Severe Neutropenia During Platinum‐Doublet Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: A Phase II Trial
- Combined Pulmonary Fibrosis and Emphysema: Current Status and Future Perspective
- Consolidation immunotherapy after concurrent chemoradiotherapy enabling conversion surgery for stage IIIB pulmonary NUT carcinoma: a case report and literature review
BibTeX
@article{yamamoto2026successful,
title = {{Successful Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer in a Patient with Combined Pulmonary Fibrosis and Emphysema: A Case Report}},
author = {Yuki Yamamoto and Shinichi Okuzumi and Naoya Murakami and Masahiko Okada and Aya Takizawa and Sayuri Iwasawa and Hisashi Yanaihara and Yusuke Suzuki},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.7961-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7961-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Successful Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer in a Patient with Combined Pulmonary Fibrosis and Emphysema: A Case Report
AU - Yuki Yamamoto
AU - Shinichi Okuzumi
AU - Naoya Murakami
AU - Masahiko Okada
AU - Aya Takizawa
AU - Sayuri Iwasawa
AU - Hisashi Yanaihara
AU - Yusuke Suzuki
PY - 2026
DA - 2026/09/29
JO - Internal Medicine
DO - 10.2169/internalmedicine.7961-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7961-26/_article
AB - Interstitial lung disease (ILD) is a major risk factor for severe radiation pneumonitis (RP) during thoracic radiotherapy. We herein report a case of limited-stage small cell lung cancer with coexisting pulmonary fibrosis and emphysema treated with concurrent chemoradiotherapy. The patient exhibited fibrotic lesions consistent with a usual interstitial pneumonia pattern and a mild 18F-fluorodeoxyglucose uptake, indicating an elevated risk of RP. However, high-grade RP did not develop, likely because radiation exposure to nontarget lungs was limited. The irradiation field was spatially separated from the fibrotic regions. This case suggests that carefully selected patients with ILD may tolerate concurrent chemoradiotherapy.
SN - 1349-7235
SN - 0918-2918
ER -